PMS30 SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE TURKISH PAYER PERSPECTIVE

Abstract

To estimate the cost per responder (CPR) of ankylosing spondylitis (AS) treatment at 52 weeks with Secukinumab 150 mg versus Adalimumab 40 mg based on the Assessment of Spondyloarthritis International Society (ASAS) outcomes. The CPR is calculated by dividing the drug acquisition cost by its response rate which is based on the ASAS20 and ASAS40 outcomes. Drug acquisition costs of 52 week course of treatment was estimated considering both the first year (including the loading doses of Secukinumab) and the maintenance condition using reimbursed prices in May 2019. Number of required doses are defined according to the approved posology in the label. Matching-adjusted indirect comparison (MAIC) approach is adopted to obtain long-term ASAS response rates based on the data from MEASURE-2 and ATLAS clinical trials of Secukinumab and Adalimumab, respectively. MAIC analysis matched patient populations on key baseline parameters. MAIC analysis showed that ASAS response rates were higher for Secukinumab compared to Adalimumab at 52 weeks (ASAS20 and ASAS40 response rates for Secukinumab were 81% and 62% versus 65% and 47% for Adalimumab, respectively). Secukinumab has a lower CPR compared to Adalimumab for all ASAS outcomes. Cost per ASAS20 responder for Secukinumab and Adalimumab was $21,002 and $32,667 and cost per ASAS40 responder was $27,302 and $45,359, respectively for the first year condition with loading doses of Secukinumab. CPR for Secukinumab calculated to be lower for ASAS20 and ASAS40 outcomes by about 50% and more when compared to Adalimumab for the maintenance condition. According to the results showing that Secukinumab achieved greater ASAS responses in comparison to Adalimumab at 52 weeks, the CPR for all ASAS outcomes were consistently lower for Secukinumab compared with Adalimumab. These findings indicate that Secukinumab would be considered as a cost-efficient treatment choice for the AS treatment in Turkey.